This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at: https://awmsg.nhs.wales/.
awmsg logo



ethinylestradiol/gestodene (Apleek®)


Reference No. 2019

Publication date:
25/09/2014


Appraisal information

ethinylestradiol/gestodene (Apleek®) 60 micrograms/24 hours/13 micrograms/24 hours transdermal patch


Company: Bayer Healthcare Pharmaceuticals
BNF category: Obstetrics, gynaecology, and urinary-tract disorders
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 24/09/2014

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, ethinylestradiol/gestodene (Apleek®) cannot be endorsed for use within NHS Wales as a female hormonal contraception.
Statement of Advice (SOA)
Download